Novel NCE from an Indian research pipeline to move from the lab to the market
A Novel Therapy to treat Diabetic Dyslipidemia
Zydus becomes the 1st Indian Pharma Company to launch an NCE
It’s first-of-its kind novel action works as a lipid regulator and also provides glycemic benefits
This marks the beginning of India’s contribution to the world of drug discovery
LIPAGLYN - The novel drug for treating Diabetic Dyslipidemia
combines lipid and glucose lowering effects in one single molecule.
Key Milestones
Disclaimer : Lipaglyn is a prescription drug authorised for sale in India only and can be taken only under the advice and guidance of a registered medical practitioner.
